Abstract:Aim To investigate whether there is a difference between HDLPCHD and HDLhealth against human umbilical vein endothelial cells apoptosis in patients with premature coronary heart disease (PCHD) and the possible mechanism. Methods Blood samples of PCHD patients and healthy subjects were collected, and HDL was isolated from the blood samples. Human umbilical vein endothelial cells were treated for 24 hours with different concentrations of oxidized low density lipoprotein (ox-LDL), cell viability was detected by MTT, to identify the appropriate concentration of ox-LDL induced human umbilical vein endothelial cells cell apoptosis. Human umbilical vein endothelial cells were pretreated with different hours and different concentration of HDLhealth, then treated with the appropriate concentration of ox-LDL for 24 hours, cell viability was detected by MTT, to identify the optimal concentration and time of HDLhealth pretreated human umbilical vein endothelial cells. Human umbilical vein endothelial cells were pretreated with the optimal hours and the optimal concentration of HDLhealth and HDLPCHD, then treated with the appropriate concentration of ox-LDL for 24 hours, cell viability was detected by MTT. Annexin V-FITC/PI apoptosis detection kit was used for flow cytometry staining, Western blot was used to detect Caspase 3 and Caspase 9 protein expression, kit was used to detect the activity of reactive oxygen species (ROS), sub-fraction (HDL1-HDL10) distribution of HDLhealth and HDLPCHD were analyzed by Lipoprint System. Results Human umbilical vein endothelial cell survival rate was 60.34% after treatmented with 100 mg/L ox-LDL for 24 hours, which was significantly lower than that in the blank treatment group (P<0.05). Human umbilical vein endothelial cell survival rate was 82.01% after pretreated with 200 mg/L HDLhealth for 18 hours, which could significantly reduce the damage of ox-LDL to cells. 200 mg/L HDLhealth could significantly inhibit apoptosis of human umbilical vein endothelial cells, the expression of Caspase 3 and Caspase 9 and the production of ROS , which were induced by 100 mg/L ox-LDL. Human umbilical vein endothelial cell survival rate was 65.5% after pretreated with 200 mg/L HDLPCHD for 18 hours, and its effect was weaker than that of HDLhealth. 200 mg/L HDLPCHD could inhibit apoptosis of human umbilical vein endothelial cells, the expression of Caspase 3 and Caspase 9 and the production of ROS induced by 100 mg/L ox-LDL, but the effect was weaker than that of HDLhealth. The content of large particle (HDL1-HDL3) in HDLPCHD subgroup was lower than that in HDLhealth (28.5%±5.7% vs. 46.8%±15.2%), while the content of small particle (HDL8-HDL10) was higher than that of HDLhealth (21.4%±7.8% vs. 10.9%±5.4%). Conclusion Comparison to the HDLhealth, perhaps due to the large particle of HDLPCHD sub-fraction content (HDL1-HDL3) was lower than that of HDLhealth, while the small particle was higher than that of HDLhealth (HDL8-HDL10), resulting in antioxidant function weakened, inhibiting the apoptosis of endothelial cells induced by ox-LDL were decreased, thereby weakening or losing the role of anti-atherosclerosis.